Posted by AGORACOM-JC
at 9:27 AM on Friday, February 5th, 2021
Announced an interview with CEO Cameron Chell will air on The RedChip Money Report on Bloomberg International on Sunday, February 7, 2021 at 6 p.m. local time across Europe.
The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73 million homes and on the Bloomberg Network in Europe in 100 million homes at 6 pm local time on Sundays.
Los Angeles, Feb. 05, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced an interview with CEO Cameron Chell will air on The RedChip Money Report on Bloomberg International on Sunday, February 7, 2021 at 6 p.m. local time across Europe. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73 million homes and on the Bloomberg Network in Europe in 100 million homes at 6 pm local time on Sundays.
In the exclusive interview, Mr. Chell discusses Draganfly’s specialization in drones, sensors, and AI, the rapidly growing drone market, and Draganfly’s wide range of lucrative applications for breakthrough spectral imaging technology.
“The RedChip Money Report” delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
Posted by AGORACOM-JC
at 7:59 AM on Monday, February 1st, 2021
Received a Purchase Order from a Canadian mining company for COVID-19 test kits manufactured by 1drop Inc., and ancillary products.
The total gross sales amount of the sales is approximately $250,000 CAD, excluding shipping and courier fees.
This brings approximately $2.8M sales to date to the Canadian mining companies.
Toronto, Ontario–(February 1, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”), is pleased to announce that it has received a Purchase Order (the “PO”) from a Canadian mining company (the “Purchaser”) for COVID-19 test kits manufactured by 1drop Inc. (“1drop”), and ancillary products. The total gross sales amount of the sales is approximately $250,000 CAD, excluding shipping and courier fees. This brings approximately $2.8M sales to date to the Canadian mining companies.
Under the terms of the sale to the Purchaser, Datametrex will provide 1drop COVID-19 qPCR Detection Kits, a PCR machine, an RNA extraction machine, and RNA extraction kits. Datametrex anticipates that it has a little or no upfront costs associated with the sale of the test kits. All of the items are shipped directly from manufacturers to the purchaser’s mine operating sites.
“This further confirms Datametrex’s approach with its diverse COVID-19 product portfolio of health security products and services,” stated Marshall Gunter, CEO of Datametrex.
Posted by AGORACOM-JC
at 2:30 PM on Wednesday, January 27th, 2021
As many of you have been watching the astounding rise of GameStop (GME:NASDAQ) it’s hard not to take notice of a company whose stock has had a 52-week low of $2.57 to a recent high of $380.
You may ask what a Fortune 500 company and a digital-first omni-channel retailer who offers games and entertainment products in its over 5,000 stores and comprehensive e-commerce properties across 10 countries has in common with PlantX Life Inc. (the “Company” or “PlantX”) (VEGA:CSE) (PLTXF:OTC) an online/ brick and mortar one-stop-shop for everything plant-based has in common…
It’s simple. Ryan Cohen, GameStop (GME:NASDAQ) inside shareholder, Board Member and… Sean Dollinger, founder of PlantX Life (VEGA:CSE) (PLTXF:OTC). The relationship runs deep. Ryan Cohen and Sean Dollinger were 50/50 partners on 3 .coms. After the three websites, Cohen went on to start Chewy.com and Dollinger went on to start Namaste Technologies. Cohen exited Chewy.com with a highly publicized sale to (Petsmart (PETM: NASDAQ), Dollinger brought Namaste Technologies to a $1.2B market cap.
In August of 2020, Ryan Cohen stepped into GameStop (GME:NASDAQ), took a sizable position in the company (~12%) and obtained 3 board seats. The stock instantly attracted a cult-like following. As a result, the company’s shares went from $4 to over $380.
Sean Dollinger founded PlantX in December 2019. As of April 2020 the Company had no revenue to speak of. Fast forward 8 months to December 2020 and PlantX Life (VEGA:CSE) (PLTXF:OTC) generated gross monthly revenue of over $1M for the month. It’s interesting to point out that Cohen and Dollinger have very similar prowess especially within the e-commerce space. After-all, they learned everything about e-commerce together, and then went on their own paths to both build billion dollar e-commerce companies using the strategies they learned together.
PlantX Life (VEGA:CSE) (PLTXF:OTC) maintains a first mover advantage as the first (known) public company fully focused on the plant-based e-commerce space. The Company exhibits strong fundamentals with cash on balance sheet, no debt, low CapEx requirements and diverse revenue streams. The Company operates in three high-growth industries – the plant-based, e-commerce/technology and consumer-packaged goods sectors. PlantX continues strides for global reach with their intent to list on Nasdaq, evidence of the company’s commitment to investor accessibility and corporate growth.
Posted by AGORACOM-JC
at 9:31 AM on Monday, January 25th, 2021
The two-day event will feature presentations by eminent psychedelics companies and industry leaders
Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST
TORONTO, ON / January 25, 2021 / Novamind Inc. (CSE:NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, today announced the Company’s participation at the Psychedelics Investor Conference, hosted by KCSA Strategic Communications on Tuesday, January 26th and Wednesday, January 27th from 9:00 AM – 12:30 PM EST.
The two-day event will feature presentations by eminent psychedelics companies and industry leaders. Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST.
“We look forward to connecting with industry leaders and investors to discuss Novamind’s operating model for clinical care and clinical research in psychedelic medicine,” said Conforti.
Posted by AGORACOM-JC
at 7:49 AM on Monday, January 25th, 2021
Announced a partnership agreement with BOOK YOUR STADIUM ( www.bookyourstadium.com ) to deliver ‘one-of-a-kind’ AR experiences from historical soccer clubs in LaLiga ( Spain ) to fans around the world.
The clubs which BOOK YOUR STADIUM is currently offering in the platform are REAL MADRIDCF , REAL SOCIEDAD CF , REAL VALLADOLID CF, VALENCIA CF, ATHLETIC CLUB , CA OSASUNA , REAL BETIS BALOMPIÉ, and RC CELTA .
Throughout 2021, several national and international clubs are expected to join the platform.
VANCOUVER, BC and ERIE, Pa. , Jan. 25, 2020 – ImagineAR (IP:CSE) (IPNFF:OTCQB) an Augmented Reality company that enables sports teams, entertainers, brands and businesses to instantly create immersive global mobile phone AR campaigns, is excited to announce a partnership agreement with BOOK YOUR STADIUM ( www.bookyourstadium.com ) to deliver ‘one-of-a-kind’ AR experiences from historical soccer clubs in LaLiga ( Spain ) to fans around the world. The clubs which BOOK YOUR STADIUM is currently offering in the platform are REAL MADRIDCF , REAL SOCIEDAD CF , REAL VALLADOLID CF, VALENCIA CF, ATHLETIC CLUB , CA OSASUNA , REAL BETIS BALOMPIÉ, and RC CELTA . Throughout 2021, several national and international clubs are expected to join the platform.
Joaquín Martínez, CEO of BOOK YOUR STADIUM , states: ” We have developed a revolutionary online e-commerce fan engagement site and incorporated ‘best of breed’ innovative digital products. ImagineAR is a leader for sports fan AR engagement and we are going to partner on unique fan AR immersive experiences featuring top LaLiga soccer club players. Additionally, we are now an authorized ImagineAR partner to market their SDK platform to LaLiga clubs for integration into their existing mobile apps which are used by tens of millions of fans around the world.”
BOOK YOUR STADIUM ( www.bookyourstadium.com ), currently available in Spanish, is expected to be available in English in February 2021 and expand globally. Initially, soccer fans can choose from over 200 experiences, adapted to the current health restrictions, to select from historical clubs in LaLiga. Some examples of experiences available include: access to virtual match experiences with exclusive content and games, e-sports matches with football players, Immersive AR experiences, virtual autographs, original match day events, or enjoy club lunch at home. In addition, there is the option of the SPORTBOX® , a themed gift box full of surprises with selected experiences from some clubs.
Posted by AGORACOM-JC
at 7:44 AM on Monday, January 25th, 2021
Initiatives and developments outlined below are in line with our larger goal of being the market leader in workplace health and safety by offering artificial intelligence powered technologies which address the major issues encountered in workplaces
Successfully deployed its technologies for beta testing purposes with major partners in North America and Asia, including India Oil (a fortune 500 corporation), MGM Hospital COVID-19 ward (one of the largest COVID-19 hospitals in Mumbai, India) and Flow Water.
Deployment at MGM Hospital is strategic to ensure our AI algorithms adapt to symptom associated changes brought on by new COVID-19 variants.
In other words, this allows our AI algorithm to adapt to the mutating virus.
Once learned, the technology is deployed immediately and is simultaneously functional across all present deployments.
TORONTO, Jan. 25, 2021 — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF)(“Predictmedix” or the “Company”) is pleased to provide a corporate update on its recent activities. This update will outline current progress, advancements of the Company and shed light on other corporate developments as the past few months have been about laying the groundwork for our long-term success. The initiatives and developments outlined below are in line with our larger goal of being the market leader in workplace health and safety by offering artificial intelligence powered technologies which address the major issues encountered in workplaces.
Public showcase of our technology in New York City
Predictmedix and Juiceworks’ Safe Entry Station will be showcased in a Live event on Jan 26, 2021 in New York City by Wellness4Humanity.
Wellness4Humanity’s New York City (NYC) flagship location opens at 225 West 34th Street near Pennsylvania Station in the heart of Herald Square in the two-story high-impact space formerly occupied by Lane Bryant. The flagship location will be showcasing a Safe Entry Station powered by Predictmedix’s proprietary infectious disease symptom screening technology.
Posted by AGORACOM-JC
at 6:53 PM on Thursday, January 21st, 2021
Today’s press release from HPQ might have been a little technical for newcomers but the words from CEO Bernard Tourillon explain exactly how important it was:
“With the Gen1 PUREVAP TM NSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications ….. We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”
Moreover, Tourillon couldn’t help but display his feelings and proclaimed this was going to be a fun year for HPQ.
Posted by AGORACOM-JC
at 8:18 AM on Thursday, January 21st, 2021
Low-Cost Manufacturing of Nano Silicon Materials
Gen1 NSiR system performance exceeded design and modelling expectations: • Successfully produced sub 100 nm silicon – based spherical nanopowders & nanowires. • Computer models suggested that the size limit of the material produced would be between 100 nm and 200 nm.SEM-XRD analysis indicates that the < 100 nm Si base spherical nanopowders & nanowires material could be used as anode material for Li-ion batteries, combined with graphite or not.
MONTREAL, Jan. 21, 2021 — Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or “the Company”) ( TSX-V: HPQ ; FWB: UGE ; Other OTC : URAGF ), through its wholly – owned subsidiary, HPQ Nano Silicon Powders inc (“HPQ NANO”), is pleased to update shareholders on milestones achieved during ongoing Gen1PUREVAPTMNano Silicon Reactor (“NSiR”) commissioning tests conducted by technology provider PyroGenesis Canada Inc. ( TSX: PYR ) .
“With the Gen1 PUREVAPTMNSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications, as we continue working on scaling up the capabilities of our PUREVAPTMNSiR process.” said Bernard Tourillon, President and CEO HPQ Silicon.
PUREVAPTMNSiRLOW-COST PROCESS: FIRST RESULTS ENCOURAGING, MORE TESTING TO FOLLOW
The material produced, under the less than optimum operating conditions of the first commissioning tests, was analysed by scanning electron microscope (SEM) imaging combined with X-ray diffraction (XRD) and yielded the following information:
Gen1 NSiR system performance exceeded design and modelling expectations: • Successfully produced sub 100 nm silicon – based spherical nanopowders & nanowires. • Computer models suggested that the size limit of the material produced would be between 100 nm and 200 nm.
SEM-XRD analysis indicates that the < 100 nm Si base spherical nanopowders & nanowires material could be used as anode material for Li-ion batteries, combined with graphite or not.
Samples from these commissioning tests have been sent to Professor Lionel ROUÉ of the CentreÉnergieMatériauxTélécommunications (EMT) for electro-chemical evaluation.
Using results from data collected during these preliminary tests, PyroGenesis technical team has improved the design of the system and the operational parameters of the reactor. • It will be possible to provide further inputs and controls on the process to customize the composition and size of the spherical nano powders and nano wires.
The Gen1 NSiR is now ready to commence further testing of Silicon nano materials under new conditions, with a goal of producing larger size Silicon (Si) nanopowders and nanowires.
A METHODICAL APPROACH TO THE COMMERCIAL DEVELOPMENT OF OUR DISRUPTIVE TECHNOLOGY
Despite massive investment in Silicon material for batteries , current manufacturing processes are simply not scalable or commercially viable. The PUREVAPTMNSiR represents a game changing leap forward in resolving the issues of commercial viability and scalability, and with the Gen1 NSiR now operational, HPQ NANO is uniquely well positioned to offer industry participants a wide spectrum of products for testing.
The scale of the Gen1 PUREVAPTMNSiR allows HPQ NANO technical provider PyroGenesis to take full advantage of a quick R&D feedback loop during the testing phase. Over short periods, tests are completed, material produced is analysed by scanning electron microscope (SEM) imaging combined with X-ray diffraction (XRD), operational parameters are reviewed and system modifications and/or operational improvements are implemented. This is the key to our methodical approach of developing a truly disruptive low-cost technology that is going to change nano silicon materials manufacturing.
Tourillon added “HPQ’s Silicon R&D consortiumhasthe depth and flexibility to meet the challenges as we strive to produce products for renewable energy storage participants and electric vehicle manufacturers, who are searching for cost effective ways of increasing the Silicon contained in their batteries. Silicon’s potential to meet energy storage demand is undeniable, generatingmassive investments,and serious industry interest.We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”
Posted by AGORACOM-JC
at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight.
Saviuk agreed and gave the following reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease. What does this mean?
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
Hesperidin may help against Covid-19 viral replication
Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.
Now you have it. That’s the Valeo story as it applies to just 2 of their amazing products. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
